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Cathepsin D (EC 3.4.23.5) is an aspartyl endopepti-
dase, like cathepsin E, pepsin, gastrixin and rennin.
Aspartyl endopeptidases are synthesized by malaria
sporozoites, sheep liver fluke Fasciola hepatica, fungi
Candida albicans and human immunodeficiency virus
HIV [1-5]. Cathepsin D is synthesized in the rough
endoplasmic reticulum (RER) in a form of prepro-
cathepsin D, built up of 412 amino acid residues [6,7].
The RER is the site of  glycosylation and formation of
disulphide bridges in preprocathepsin D. Splitting off
of the N-terminal 20 aminoacid prepeptide by sig-
nalase causes release of procathepsin D and its passage
to the Golgi apparatus and primary lysosomes. In an
acid environment of the primary lysosomes, intramol-
ecular autocatalytic splitting off of the 44 amino acid
propeptide and the formation of active enzyme  occur
[8-12]. The actions of cysteine proteases, aminopepti-
dases, carboxypeptidases and the autocatalytic process
lead to the formation of a mature two-chain cathepsin
D molecule, 12 + 34 kDa, [13,14]. These protease
inhibitors inhibit maturation of cathepsin D [15],
which can also be found on the cell surface due to
fusion of lysosomes with the plasma membrane
[16,17]. Cathepsin D may pass to cytosole, to the intra-
cellular environment and to the blood.
The catalytic site of cathepsin D consists of two
aspartic acid residues: Asp33 and Asp231 [18], which
together with water molecule cause hydrolysis of pep-
tide binding. The ionized carboxyl group of the Asp33
residue activates the water molecule and facilitates
proton detachment. The protonated carboxyl group of
the Asp231 residue, in an acid environment, polarizes
the carboxyl group of the substrate peptide binding,
facilitates formation of indirect tetraedric product and
increases its vulnerability to cleavage. The cleavage
refers to the peptide binding situated within the
polypeptide chain formed by carboxyl groups of
hydrophobic amino acids [19].
Cathepsin D is involved in the process of degrada-
tion of exploited and denaturated cell proteins and
those reaching the cell via endocytosis [20,21]. It also
affects proteins indirectly through activation of pro-
cathepsin B [22,23], procathepsin L [24] prorenin [25]
and inactivation of cystatins [26,27], stephins [26], and
inhibitors of seryl protease type 1-2 [28], urokinase
type 1-3 [28, 29], α1-antithrypsin [30], α1-antichy-
mothrypsin [31] and calicrein [31]. Cathepsin D is also
engaged upon selective proteolysis, which leads to the
activation of prohormons and biologically active pep-
tides and to the inactivation of their active forms
[16,27,32-37]. Moreover, it takes part in the formation,
development and regression of such pathological
changes as inflammatory states, atherosclerosis,
intravascular thrombi, apoptosis, mutagenesis, neo-
plastic proliferation or Alzheimer disease [38-53].
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Cathepsin D activity is regulated on a few levels:
through stimulation and inhibition of its biosynthesis,
at the stage of post-translatory modifications in the
Golgi apparatus, proenzyme activation and interlyso-
somal pH regulation [54-56]. This ensures that cathep-
sin D can operate at the proper time, site and intensity,
and prevents uncontrolled protein degradation. The
20-kDa cytoplasmic protein, glycine ethyl ester,
tripolyphosphates, phospholipids and ATP increase the
activity of cathepsin D [57-59].
Cathepsin D degrades proteins at pH=3.5-5.5 [60].
Binding of this protease to a constant carrier shifts
digestion towards neutral pH [61]. Vulnerability to
degradation by cathepsin D depends also on the pro-
tein molecular structure. Haemoglobin and other
denaturated proteins are more prone to the action of
this protease than native proteins. However, complex-
ification of haemoglobin with haptoglobin causes a
reduction in the optimum pH from 3.5 to 2.8 and at the
same time a 50% decrease in degradation rate [62].
Definition and division of cathepsin D
inhibitors                                                            
The inhibitor is a compound showing chemical affini-
ty toward an enzyme or bearing structural similarity to
a substrate which binds to the catalytic site of an
enzyme and forms an inactive enzyme-inhibitor com-
plex. Chemical compounds reducing the enzyme activ-
ity via another mechanism are referred to as inactiva-
tors. Inactivators do not exhibit specificity for a partic-
ular enzyme or group of enzymes and include such
protein-denaturating agents as heavy metal salts, alka-
loid reagents, tannins, detergents, acids and bases, and
elevated temperature. The inhibitors can be divided
into competitive, noncompetitive and mixed, immedi-
ate and progressive, monovalent and polyvalent, syn-
thetic and natural, endogenous and exogenous. The
Lineweaver-Burk equations and plots are used to
determine the competitive, noncompetitive and mixed
types of inhibitors [63-66]. Based on the experimental
data obtained for various inhibitor concentrations, the
Michaelis constant and the maximum velocity are
determined. The values obtained are placed in a plot
showing the relationship of the reciprocal of the
Michaelis constant and the reciprocal of the maximum
velocity with the inhibitor concentration. Depending
on the type of inhibitor,  the curves may show either
increased inclination or a shift of the point of intersec-
tion with the axis of ordinates. The competitive
inhibitor shows structural similarity to a substrate with
which it competes for an enzyme's catalytic site. It
reduces substrate affinity for an enzyme and increases
the Michaelis constant (1/Km). However, the maxi-
mum velocity, under substrate excess, remains stable
(1/Vmax). This causes increased inclination of the
Lineaweaver-Burk plot, at the same point of intersec-
tion with the axis of ordinates as when the inhibitor is
absent (Fig. 1A). The noncompetitive inhibitor has the
substrate structure and binds to the enzyme outside the
catalytic site. Such an inhibitor does not alter the
Michaelis constant (1/Km), but decreases the maxi-
mum reaction velocity (1/Vmax), which leads to
increased inclination of the curve and to a shift of the
point of intersection with the axis of ordinates (Fig.
1B). The mixed inhibitor, which is partly competitive
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Fig. 1. Determination of the inhibition constant by the  double-
reciprocal plot method; A - competitive inhibition, B - noncom-
petitive inhibition, C - inhibition of the mixed type; Ci - competi-
tive inhibitor, Ni - noncompetitive inhibitor, Mi - mixed type
inhibitor [63].
and partly noncompetitive, binds to free enzyme and to
the enzyme-substrate complex. In the Lineweaver-Burk
plot, both the Michaelis constant (1/Km) and the maxi-
mum velocity (1/Vmax) increase (Fig. 1C). Mixed
inhibitors hinder the formation of the enzyme-substrate
complex and decrease the velocity of formation and
release of the reaction product. Mixed type inhibition
can be also observed when cathepsin D exerts a simul-
taneous effect on different substrates, including a mix-
ture of protein partial degradation products having var-
ied affinity for this protease [67]. The inhibitor acts
competitively toward some substrates and noncompet-
itively toward others. Characteristic features of various
types of inhibitors have been presented in Table 1.
Pepstatin acts as an inhibitor of cathepsin D and
other aspartyl proteases (Table 2). It does not inhibit
the activities of seryl cathepsins, cysteinyl cathepsins
or metalloproteases, and their inhibitors do not block
the activity of cathepsin D. A properly chosen set of
inhibitors allows differentiation of cathepsin D from
cathepsin A and B (Table 3), and from cathepsin E,
pepsin and rennin, which are also aspartyl proteases
(Table 4). Dithiotreitol, at a concentration of 1 mmol/l,
pH=8.0, inactivates this cathepsin [69]. However,
endogenous thiols, at physiological concentrations, do
not affect cathepsin D activity.
The propeptide split off of procathepsin D during
activation [70,71], α2-macroglobulin [72] and DNA
fragments [73] are endogenous cathepsin D inhibitors.
Their inhibitory effects are slight and observed only in
special conditions. Most cathepsin D inhibitors are
synthetic, peptide and polypeptide produced by
microorganisms, plants and animals [67,74-77]. Spe-
cific anti-cathepsin D antibodies also have an inhibito-
ry effect. 
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Table 1. Properties of different types of inhibitors: competitive, noncompetitive and mixed type.
Table 3. The inhibitory effect of pepstatin A, antipain, leupeptine and chymostatin on cathepsins A, B and D [68].
Table 2. Inhibitor susceptibility of proteases with different struc-
ture of catalytic site. x - L-3-carboxy-2,3-trans-epoxy-propionyl-
leucylamido(guanidino)butane; xx - 3,4-dichloroisocumarine.
Table 4. Vulnerability of human aspartyl proteases to inhibitors. *
+ inhibitory effect, - lack of inhibition.
Synthetic inhibitors                                            
Synthetic inhibitors of cathepsin D are micromolecular
organic compounds estrifying the carboxyl group of
the Asp33 or Asp231 residue in the catalytic site. The
Asp33 residue reacts with  1,2-epoxy-3-(p-nitropheny-
loxy)-propan (Fig. 2). The compounds reacting with
the Asp231 residue include diazacetyl derivatives of
amino acid methyl esters. The carboxyl groups of
cathepsin D are estrified by these compounds in the
presence of copper ions having a catalytic function
[78]. The reaction of cathepsin D with diazoacetyl nor-
leucine methyl ester has been presented in Fig. 3.
Other cathepsin D inhibitors are: diazoacetyl-glycine
ethyl ester  [79], diazoacetyl-phenyloalanin methyl
ester [80], diazoacetyl-2,4-dinitrophenyl-ethylenedi-
amine [81] and other diazol compounds [81-85]. The
reaction of cathepsin D with diazol compounds occurs
most rapidly at pH=4.5. Other cathepsin D inhibitors
also include many derivatives of 4-(morpholinyl-
sulphonyl)-L-Phe-P2-(cyclohexyl)Ala[isostere]-P1'-
P2', listed in Table V. Also ditiophosgen and 2,2-
dichloro-1,3-ditiocyclobutanone [87], and methyl blue
and tetranitrometane [88] have been found to inhibit
cathepsin D activity. These compounds inactivate
pepsin as well. However, 2,4'-dibromoacetophenone
and 2-bromo-2-phenylacetophenone inhibit pepsin but
not cathepsin D activity [78,89,90].
Synthetic substrate analogues                             
Cathepsin D activity is inhibited by structural ana-
logues of synthetic substrates. These are oligopeptides
containing at least five amino acid residues in the mol-
ecule and having L-amino acid replaced by D-amino
acid. In the pentapeptide Pro1-Phe2-Phe3-Val4-Leu5,
cathepsin D causes the cleavage of the Phe2-Phe3
bond [91]. Replacement of L-Leu5 residue by D-Leu5
makes this pentapeptide resistant to the action of
cathepsin D and able to inhibit hydrolysis of matrix
pentapeptide. In the Gly1-Phe2-Leu3-Gly4-Phe5-
Leu6 hexapeptide, cathepsin D causes the cleavage of
the Phe2-Leu3 bond. The hydrolysis of peptides of
analogous structure but containing D-amino acids in
positions P1, P3 or P4 is considerably hindered; more-
over they inhibit decomposition of a hexapeptide built
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Fig. 2. Reaction of cathepsin D Asp33 ionized residue (1) with 1,2-epoxy-3-(p-nitrophenoxy)-propane (2); (3) 2-hydroksy-3-(p-nitrophe-
noxy)propyl ester [63].
Fig. 3. Reaction of cupric chloride with diazoacetyl norleucine methyl ester (1) with creation of carbene with cupric ions complex chlo-
ride (2); nonionised Asp231 residue of cathepsin D (3) with carbene with cupric ions complex chloride (2) with creation of 2-oxo-3-ase-
4-metoxycarbonyloxyl ester (4) [63].
up of L-amino acids. Cathepsin D vulnerability to
hydrolysis and degree of inhibition by these ana-
logues depend on the number and location of D-
amino acids in the molecule (Table 6). The analogues
with one D-amino acid at a maximum distance from
the site sensitive to cathepsin D exert the strongest
inhibitory effect. However, the analogues with two
D-amino acids at the site of a cleaved Phe3-Leu3
bond and constituting a cyclic hexapeptide are not
hydrolyzed and do not exhibit an inhibitory effect.
This has been also confirmed by data shown in Table
7. Cathepsin D activity is also inhibited by Gly-Glu-
Gly-Phe-Leu-Gly-D-Phe-Leu and aldehydes of such




Table 5. Inhibition constant (Ki) of 4-(morpholinylsulphonyl)-L-Phe-P2-(cyclohexyl)Ala(isostere)-P1-P2 derivatives, in relation to
human aspartyl proteases [86]. Abbreviations: ACFHP - 4-amino-5-cyclohexyl-2,2-difluoro-3-hydroxypentanamides; AEM - 2-mor-
pholinylethylamide; MBA - 2-methylbutylamide; ACFOP - 4-amino-5-cyclohexyl-2,2-difluoro-3-oxopentanamides; 3.4-ACDMH - 2-
amino-1-cyclohexyl-3,4-dihydroxy-6-methylheptane; ACDPD - 2-(2-amino-1-cyclohexyl-3,5-dihydroxypent-6-yl)-1,3-dithiane; 3.5-
ACDMH - 2-amino-1-cyclohexyl-3.5-dihydroxy-6-methylheptane; R-ACDH - 5(R)-2-amino-1-cyclohexyl-3,5-dihydroxyheptane; S-
ACDH - 5(S)-2-amino-1-cyclohexyl-3,5-dihydroxyheptane. 
Table 6. Inhibition of release of the dipeptide Gly-Phe from the substrate Gly-Phe-Leu-Gly-Phe-Leu by cathepsin D in the presence of
its D-isomers [91].
Inhibitors produced by microorganisms             
Inhibitors of aspartyl proteases are synthesized by
Streptomyces testaceus, Streptomyces argenteolus
and other species of the genus Streptomyces. These
inhibitors are called pepstatins as they inhibit the
activity of pepsin. They also inhibit the activities of
cathepsin D, cathepsin E, renin, pseudorenin, aspartyl
proteases produced by microorganisms and plants
[94-98].
Pepstatins are pentapeptides containing non-amino
acid constituents, typical amino acids and atypical
amino acid. They are composed of a sequence of 1 acyl
radical, 2 valin residues, 1 statin residue, 1 alanine
residue and 1 statin residue, and are shortly called Ac-
L-Val-L-Val-L-Sta-L-Ala-L-Sta. Statin (Sta) is a rare
atypical amino acid referred to as [(4S,3S)-4-amino-3-
hydroxy-6-methylheptanoic acid] (AHMHA) (Fig. 4).
Pepstatins differ from each other in the structure of the
acyl radical (Fig. 5). Hydroxypepstatin and pepstanon
are pepstatin derivatives with preserved inhibitory
potential. Hydroxypepstatin contains serine instead of
alanine. In pepstanon, at the site of C-terminal Sta, its
ketone 3S-3-amino-5-methylhexanone-2 (AMHN) is
located. The isovalerian acid residue is the most com-
mon acyl, hydroxypepstatin and pepstanon residue
(Fig. 6). The structure of acyl residue of pepstatins
depends upon culture conditions. Streptomyces tes-
taceus grown in a medium containing meat extract
generates isovaleryl pepstatin, whereas that cultured in
a medium with casein produces hexanol-pepstatin. 
The hydroxyl group Sta4 is directly involved in the
inhibitory action of pepstatins, reacting with the catalyt-
ic-site residues of an aspartyl protease [102]. The Sta4
residue is a structural analogue of substrate, analogue of
its transitory state and shows an inhibitory action due to
structural similarity to the tetraedric immediate product
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Table 7. Inhibition of cathepsin D and pepsin action by synthetic
peptides [92].
Fig. 4. Statin.
Fig. 5. Structure of pepstatins, hydroxypepstatin and pepstanones. *- acyl radical R1- the same as pepstatins A-H [100].
formed during cleavage of peptide bonds by proteases
possessing carboxyl catalytic sites (Fig. 7). The mecha-
nism of cathepsin D activity inhibition by pepstatin can
be illustrated by a simplified model (Fig. 8) and a spa-
tial model of these substances (Fig. 9). Hydrogen bonds
connecting pepstatin to cathepsin D have been listed in
Table 8. Pepstatin also binds to procathepsin D and
inhibits its autoactivation [106].
The inhibition of aspartyl protease action by pep-
statins depends to a large extent on the presence of
acid residue in their structure [107]. A comparison
between the inhibitory effect of pepstatins with vari-
ously structured acid residue on the activities of
pepsin, cathepsin D and rennin shows that the inhibito-
ry effects are similar in the case of the first two pro-
teases, whereas that of rennin increases with elonga-
tion of carbon chain of the residue (Table 9). This is
due to the structural similarity of the catalytic site of
pepsin and cathepsin D and its different structure in the
rennin molecule. Differences in the inhibitory action
are also observed according to the type of the N- and
C-terminal group (Table 10). The inhibitory effect of
pepstatins on cathepsin D does not depend on the car-
bon chain length of the acid radical. Hydroxypepstatin
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Fig. 6. Pepstatin A, hydroxypepstatin A and pepstanone A [101].
Fig. 7. Tetraedric intermediate state of the substrate (A) and stable analogue of intermediate tetraedric state which is hydroxymethylene
residue (B) [103].
exerts a similar inhibitory effect to that of pepstatins.
However, the inhibitory effect of pepstanon is less
pronounced. This indicates the significance of the
presence of hydroxyl groups in the C-terminal frag-
ment for the action of these inhibitors (Table 11).
The activity of cathepsin D is also inhibited by
methyl ester of carbobenzoxy Z-Arg-Arg-Pro-Phe-
His-Sta-Ile-His-Lys [110].
The splitting off of the Ac1 and Val2 residues by
pepstatin peptidase synthesized by Bacillus Sphericus
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Fig. 8. Cleavage of a peptide bond -Phe4-Phe(NO2)5 by cathepsin D in a substrate and pepstatin inhibition of this process, according to
Schecter and Berger [104]. S4-S3' - aminoacidic residues of catalytic site, P4-P3' - substrate or pepstatin aminoacidic residues, arrow -
cleaved peptide bond, * - NO2.
Fig. 9. Interactions between pepstatin
and cathepsin D. Schematic hydrogen-
bonding diagram for pepstatin bound to
cathepsin D. Inhibitor side chain num-
bering as according to the nomenclature
of Schechter and Berger, where Pn des-
ignates inhibitor side chain residues
that interact with the corresponding Sn
subsites within the enzyme active site.
Iva and Sta indicate isovaline and
statin, respectively [102,105].
inactivates pepstatins (Table 12). The action of this
enzyme is conditioned by the N-terminal sequence
Ac1-Val2-Val3-, from which acyl radical and N-termi-
nal valin are released. The splitting of the acyl and
valin residues off pepstatin A causes a considerable
reduction in the inhibitory activity towards cathepsin
D, pepsin and rennin (Table 13). Addition of the acyl
residue, varying according to its type, increases the
inhibitory activity. 
Methods in combinatorial chemistry are used in
studies on modification and synthesis of new pepstatin
derivatives [113-116].
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Table 8. Hydrogen bonds between cathepsin D and pepstatin; *
aminoacid residues of the active site [102].
Table 9. Inhibition of cathepsin D, pepsin and renin by pepstatins
[101].
Table 10. Inhibition of cathepsin D, pepsin and renin activity by pepstatin and pepstatin derivatives [108].
Table 11. Peptide aldehydes with inhibitory activity against cathepsin D [109]. Comparison with pepstatin. 
Polypeptide plant inhibitors
Polipeptide inhibitors of aspartyl proteases can be
found in spare plant organs such as seeds, bulbs and
fruits, and more seldom in vegetative organs like
leaves, roots and flowers. They protect plant proteins
against uncontrolled actions of endogenous and exoge-
nous proteases synthesized by parasitic viruses, bacte-
ria, moulds and insects [117-121].
Well defined amino acid residues constituting the
inhibitory reactive site, complementary  to the amino
acid residues of the protease catalytic site, are found
on the surface of the polypeptide inhibitor molecule.
The type of amino acid residues of this site determines
the group and individual specificity of the inhibitor. This
can be a sequence specific to the catalytic sites of
aspartyl proteases or to the catalytic site of a particular
protease, also cathepsin D. The inhibitor forms a per-
manent complex with an in the 1:1 ratio and blocks the
action of cathepsin due to hydrophobic and ionic hydro-
gen bonds of the reactive site of the inhibitor, the cat-
alytic site of cathepsin and their closest environment. 
Potato inhibitors of cathepsin D        
Potato bulbs contain six or eight polypeptide inhibitors
of cathepsin D, depending on the species [105,122-
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Table 12. Substrate specificity of pepstatin hydrolase [111].
Table 13. Inhibitory activities of Val-AHMHA-Ala-AHMHA, its N-acylated derivatives and pepstatin A against cathepsin D, pepsin and
renin [112].
131]. They show a considerable similarity in the amino
acid composition, sequence (Fig. 10) and in the num-
ber and location of disulphide bridges. Potato
inhibitors possess two inhibitory sites: one binding
cathepsin D and the other binding trypsin [133], and
they do not inhibit the activity of pepsin. Inhibitors of
aspartyl proteases also occur in potato leaves [134]. 
Inhibitors from pumpkin fruit                              
Cathepsin D inhibitor, which also inhibits the activity
of pepsin and acid protease from fungus Glomerella
cingulata has been isolated from pumpkin fruit [135].
It is composed of 96 amino acid residues and occurs in
three molecular forms differing slightly in the amino
acid sequence. Two molecular isoforms are found to
predominate (Table 14) and are called DNIS and
HDVA due to differences in the amino acid sequence
(Fig. 11). The sequence, however, is very similar, espe-
cially in the N-terminal sequence (MGPGPAIGEVIG)
and in the internal sequence (FYNVVVLEK). These
inhibitors do not contain cysteinyl residues or sugar
constituent. The molecular mass of DNIS isoform is
10551 Da, and of HDVA isoform - 10527 Da. These
isoforms constitute a dimeric form with a molecular
mass of 21000 (10551 + 10527). During purification,
the dimeric form breaks down and monomers preserve
their activity. The inhibitor is permanent in an acid and
neutral environment, but sensitive to alkalization and
elevated temperature. 
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Fig. 10. Aminoacid sequences of aspartic protease inhibitor from potato. * - identical amino acid residues; :. -  conserved amino acid
residues [132]. 
Inhibitors synthesized by other plants
Cathepsin D inhibitors can be found in the seeds of
lentil and vicia [136], but are not found in the seeds of
25 cereal species and pulses consumed by man.
Cathepsin D inhibitors have been isolated from the
seeds of wheat [137], barley [138], tomato leaves
[139-141], tobacco leaves [142], aubergine fruit
(Solanum melongea) and from trailing nightshade
leaves (Solanum dulcamara) and black nightshade
(Solanum nigrum). The inhibitor obtained from toma-
to leaves inhibits the activity of the proteases listed in
Table 15. The effects of cathepsin D inhibitors isolated
from tomato leaves and potato bulbs have been com-
pared in Table 16.
The synthesis of plant cathepsin D inhibitors is
stimulated by mechanical tissue injury  [144], as well
as jasmonic acid, methyl ester of jasmonic acid and
abscisic acid [145-149]. Salicylic acid inhibits synthe-
sis of these inhibitors [150]. 
Techniques of molecular biology have been used to
obtain plant cathepsin D inhibitors [146,151,152].
Inhibitors synthesized by lower animals   
Cathepsin D activity is inhibited by equistatin, a pro-
tein inhibitor isolated from Actinia equina [153,154].
Equistatin inhibits the activity of cystein proteases:
papain, cathepsin B, cathepsin L and cathepsin D, but
not the activity of pepsin, chymotrypsin or HIV pro-
tease. Equistatin has a domain structure (Fig. 12).
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Table 14. Aminoacidic composition of DNIS and HDVA inhibitors
isolated from pumpkin fruit [135].
Fig. 11. Amino acid sequences of  DNIS (a) and HDVA (b) iso-
forms of squash aspartic proteinase inhibitor [135].
Table 15. Inhibitor isolated from tomato leaves and inhibitory
effect on different aspartyl proteases [143]. All measurements
were performed in pH=4.7.
Table 16. Inhibition of cathepsin D activity indifferent pH by
inhibitor isolated from tomato leaves and potato bulbs [143].
Trypsin digestion of equistatin leads to the formation
of domain-1 and domain-2 and 3, which are connected
by the disulphate bridge. These domains originate
from cleavage of the peptide bonds Lys67-Ala68 and
Arg151-Val152. Trypsin also splits the inactive C-ter-
minal fragment off domain-3. Domain-1 inhibits the
activity of cystein proteases (papains), whereas
domain-2 and domain-3 inhibit the activity of cathep-
sin D (Table 17).
Ascaris lumbricoides and Ascaris suum synthesize
the inhibitors which block the activity of  cathepsin E,
pepsin and rennin but not cathepsin D  [155-158].
They are used to differentiate the activities of these
proteases in the nonfractionated material. The activity
of the inhibitor from Ascaris suum towards aspartyl
proteases has been presented in Table 18.
Endogenous cathepsin D inhibitors                    
Endogenous cathepsin D inhibitors include α2-
macroglobulin and polyanion compounds - glycoza-
minoglycans and deoxyribonucleic acids.
The α2-macroglobulin (α2-M), a 725,000-Da gly-
coprotein, is built up of four structurally, elec-
trophoretically and immunologically identical
185,000-Da subunits.  Each subunit is composed of
1,451 amino acid residues and contains 8 oligosaccha-
ride chains. The subunits combine to form dimers by
means of disulphide bonds Cys225-Cys408 and Cys-
447-Cys540. The dimers attached to hydrogen- and
hydrophobic-bonds form a tetramer. The α2-M differs
from typical inhibitors in protease binding and low
specificity, and it shows a two-stage interaction with
proteases. In the first stage, protease recognizes a spe-
cific peptide bond in the central fragment of the
polypeptide chain of each subunit with approximately
45 amino acid enzymes [160,161]. In this fragment,
peptide bonds formed by residues of 15 amino acids
meet the specificity requirements of each endopepti-
dase ("bait" principle) [162]. Therefore, the α2-M is a
universal broad-spectrum inhibitor, reducing the activ-
ity of all four endoprotease classes [163-165]. In the
case of cathepsin D, the -Phe684-Tyr685- bond under-
goes cleavage. However, the α2-M exerts no effect on
the activity of exopeptidases, as the peptide bond situ-
ated within the chain cannot be cleaved by aminopep-
tidases, carboxypeptidases, tripeptidases and dipepti-
dases. Specific peptide bond cleavage causes a rapid
change in the conformation of all subunits and pro-
tease arrest in stage two ("trap" principle). Thus, pro-
tease becomes inaccessible to protein substrates and
macromolecular inhibitors. Immediate conformatory
changes in both α2-M subunit pairs block the binding
of the second protease molecule. It means that only
one α2-M molecule binds only one protease molecule.
The other protease molecule can be bound by α2-M
following cleavage of the peptide bond in the second
pair of subunits, prior to conformatory changes initiat-
ed by the first molecule. Then, the two protease mole-
cules are bound at two independent but equivalent sites
of the α2-M molecule, which may occur only at a high
concentration of a relatively low molecular mass pro-
tease, e.g. trypsin or chymotrypsin, but not in the case
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Fig. 12.  Schematic diagram of equis-
tatin [154].
Table 17. Inhibition constants (Ki) of aspartyl proteases and
papain with domain-1, domain-2, 3 and equistatin [154].
Table 18. Kinetic constants (Ki) for the inhibition of aspartic pro-
teases by the Ascaris suum inhibitor [207].
of cathepsin D that occurs in low concentrations in
body fluids  and possesses a relatively high molecular
mass. The reaction of α2-M with cathepsin D takes
place according to the following scheme: α2-M + KD
→ α2-Mx + KD → α2-Mx-KD. In physiological con-
ditions, cathepsin D binding to α2-M is irreversible.
The use of depolimerizing chemical compounds
allows observation of the course of cathepsin D-
induced changes in the structure of α2-M subunits
(Fig. 13). β-mercaptoethanol (1%) cleaves tetramers to
form a complete dimer and a dimer built up of a full
dimer and one half of the monomer whose other half
has been released. Dodecylosulphate  (0.1%) releases
nonconvalently bound complete and incomplete
monomers. The catalytic site of cathepsin D, occupied
by α2-M, is free. Micromolecular substrates and
micromolecular inhibitors have access to this site,
whereas the macromolecular ones do not [166]. The
α2-M inhibits the residual activity of cathepsin D at
pH=6.0-6.2, but not at a lower pH, because of structur-
al instability of this protease [167,168]. Approximately
20% of plasma cathepsin D is blocked by α2-M [169].
The remaining 80% is the procathepsin D, the inactive
precursor which does not interact with α2-M. The
above data were obtained by means of Sephadex G-75
gel chromatography using 125J-labeled cathepsin D
(Fig. 14). Pepstatin blocks the interaction between
cathepsin D and α2-macroglobulin, due to which the
amount of cathepsin D bound to the inhibitor is
reduced to approximately 8%. The α2-M is synthe-
sized in fibroblasts and then passes to the intracellular
fluid, lymph and blood [170]. In the plasma, α2-M
occurs at a concentration of 260.0 mg/100 ml (3.3
μmol/l), constituting approximately 0.4% of plasma
proteins [171]. The physiological role of α2-M is to
prevent proteins against uncontrolled proteolysis,
which takes place through binding, activity inhibition
and removal of proteases from blood plasma and intra-
cellular fluid. The α2-M-protease complexes are cap-
tured by membrane receptors of macrophages and
hepatocytes [172], undergo endocytosis and are trans-
ported to lysosomes. Then, the complexes undergo
digestion and the receptors return to the cell surface.
The antiproteolytic effect of α2-M is counteracted by
methylamine [173].
Cathepsin D reduces formation of ion complexes
with glycozaminoglycans [174] and polysaccharides
[98]. The strongest inhibitory effect is exerted by
heparin (52%), weaker by chondroitin sulphate (36%)
and the weakest by hialuron acid (10%). Reduction in
cathepsin D activity by glycozaminoglycans is pH-
dependent. The greatest decrease can be observed at
pH=4.0-4.5, whereas at a lower pH, the inhibitory
effect is reduced. The inhibitory effect of glycoza-
minoglycans is counteracted by alkaline proteins. 
The activity of cathepsin D is also reduced by for-
mation of ion complexes with 18b and 53b DNA frag-
ments [73]. There is a correlation between the inhibito-
ry activity of cathepsin D and the melting temperature
(Tm) of a DNA molecule. These fragments also
decrease the activity of cathepsin E, but not the activi-
ty of seryl and cysteine proteases. 
Antibodies                                                          
Cathepsin D (antigen) introduced parenterally to
another species induces production of antibodies (anti-
enzymes). Antigen determinants and catalytic sites of
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Fig. 13. Schematic structure of α2-macroglobulin binding with cathepsin D (KD) and action  of β-mercaptoethanol (β-Me) and dodecyl
sulphate (SDS) on inhibitor-cathepsin D complex. ≡ - "bait" region, 1 - tetramer, 2 - tetramer-cathepsin D complex, 3 - dimer-cathepsin
D, 4 - dimer, 5 - cathepsin D, 6 - fragments of monomer, 7 - monomers.
Fig. 14. Gel chromatography of 125I-labelled cathepsin D [169].
Cathepsin D and α2-macroglobulin - solid line, cathepsin D with
pepstatin and α2-macroglobulin - stroked line.
cathepsin D are located at adjacent sites in a molecule.
The cathepsin D binding to an antibody hinders access
of substrate to the catalytic site [175]. The site is larg-
er for the macromolecular than it is for the micromol-
ecular substrate. The inhibitory effect also depends
upon the chemical structure of a substrate, being more
pronounced for hemoglobin than for proteoglycans
[176]. The cathepsin D has a few sequential and con-
formatory antigenic determinants against which anti-
bodies are produced. The inhibitory effect has been
shown to be exerted by antisera and isolated antibod-
ies. Anti-cathepsin D antibodies have been obtained
from Sepharose 4B-bound cathepsin D using an
immunosorption method. The inhibitory effect is also
found to be exerted by monovalent fragments of anti-
gen binding (Fab) of immunoglobulins, due to anti-
body fragmentation with papain or pepsin and distri-
bution of the products obtained in Sephadex G-75
[177,178]. Antibodies are the most specific cathepsin
D inhibitors. Their specificity is absolute, referring not
only to cathepsin D but also to its species-related ori-
gin. Antibodies directed against cathepsin D isolated
from a particular organ also inhibit the action of this
cathepsin isolated from other organs of the same
species, but do not react with cathepsin D from other
species.  Complete inhibition of cathepsin D activity
occurs at an approximately six-fold molar excess of
antibodies. The formation of the cathepsin D-antibody
complexes is most intense at pH=5.0 [179]. It is then
that cathepsin D solubility decreases and shedding
from the solution takes place. The activity of cathepsin
D measured at  pH=5.0 with the use of hemoglobin is
almost completely hampered in a reactive mixture
prior to centrifugation, in supernatant and sediment
(Fig. 15). However, the activity of cathepsin D is not
inhibited by antiserum at pH=3.2 (Fig. 16). No activi-
ty can be found in the supernatant, whereas in the sed-
iment the activity is nearly the same as with noncen-
trifuged material. Thus, due to immunoinhibition,
there is a shift in the optimum pH of cathepsin D to
acid direction [176]. The effect of immunocomplex
formation on the action of cathepsin D on proteogly-
cans has been shown in Fig. 17. Conformatory changes
in the cathepsin D complexed with antibody stabilize
the structure and cause an increase in its thermoresis-
tance. The antibodies against lysosomal proteases
accumulate in cultured fibroblast lysosomes [180].
The biological role and application 
of cathepsin D inhibitors 
The acid pH of lysosomes has a basic role in the acti-
vation of procathepsin D and activity of cathepsin D.
The propeptide released during autoactivation of pro-
cathepsin D, which at weakly acid pH binds electro-
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Fig. 15. Effect of antiserum ratio on  cathepsin D activity in
pH=5.5 [176]. o - before centrifugation, • - in supernatant, ? - in
precipitate.
Fig. 16. Effect of antiserum ratio on  cathepsin D activity in
pH=3.2 [176]. o - before centrifugation, • - in supernatant, ? - in
precipitate.
Fig. 17. Inhibitory effect of antiserum on cathepsin D activity
against 33S-proteoglicans. • - cathepsin D, ? - cathepsin D and
antibody [176].
statically to cathepsin D and inhibits its activity, also
plays a certain regulatory part [70,71]. In the case of
lysosomal damage and cathepsin D translocation to the
cytosol of the intercellular fluid and plasma, neutral
pH and α2-macroglobulin prevent uncontrolled prote-
olysis [181].
Exogenous cathepsin D inhibitors play a key role in
identification of the structure of the catalytic site of
this protease [57]. The binding of a radioisotope-
labeled inhibitor to the catalytic site of cathepsin D,
limited proteolysis and isolation of a fragment con-
taining a marker allow determination of the composi-
tion and the amino acid sequence of the site. A com-
parison of differences in sensitivity to inhibitors facil-
itates differentiation of aspartyl proteases. The activi-
ties of cathepsin E and pepsin are found to be blocked
by aspartyl protease inhibitor from human ascaris,
whereas cathepsin D and renin are insensitive to this
inhibitor. 
Cathepsin D inhibitors have analytical and prepara-
tive significance. Pepstatin has been used for quantita-
tive determination of this protease by catalytic site titra-
tion, whereas Dansyl-pepstatin for cathepsin D catalyt-
ic site titration [182]. Lysosomal protease inhibitors are
added to the solutions used to obtain subcellular frac-
tions and fractionation of cell proteins in order to pre-
vent proteolytic degradation. High specificity of bind-
ing to inhibitors allows isolation of cathepsin D by
means of affinity chromatography, using inhibitors
[20,183-186] and constant carrier-bound antibodies.
Differences in the pH values between procathepsin and
cathepsin D bonds with pepstatinyl-agarose help sepa-
rate these two forms of the enzyme [187,188]. The con-
stant carrier-bound cathepsin D is used to isolate its
inhibitors [189]. The carrier-bound propeptide allows
cathepsin isolation [190].
Pepstatin is used to determine the function of the
cathepsin D found in a mixture with other cathepsins
in protein degradation that occurs in the cell [191,192].
Inhibition of cell proliferation by pepstatin confirms
the hypothesis that this process is stimulated by
cathepsin D. The use of specific antibodies against
cathepsin D has shown its significant involvement in
degradation of macrophage proteins and cartilage pro-
teoglycans [193]. Cathepsin D is localized within cells
and tissues by means of specific fluorescein-labeled
antibodies [20]. Methylmercury derivatives of pep-
statin have been used for intracellular localization of
cathepsin D  [194]. The immunochemical method
allows differentiation between cathepsin D and cathep-
sin E [195].
Attempts have been made to use cathepsin D
inhibitors for therapeutic purposes. Synthetic
inhibitors, due to their high toxicity, cannot be used for
these purposes. Natural inhibitors can regulate proteol-
ysis velocity in vivo. Most studies have dealt with the
therapeutic application of pepstatin. Pepstatin has been
used in pathological conditions occurring with
increased cathepsin D activity, such as inflammatory
states, burns, gastric ulcer, hypertension and Shwartz-
mann - Sanarelli phenomenon [99, 103, 132, 196-200].
Its advantage consists in low toxicity and low molecu-
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Table 19. Distribution of  3H-pepstatin  after enteral introduction in mice [201].
lar weight, which permit cell and tissue penetration.
Pepstatins can be administered orally or intraperi-
toneally. Pepstatin dose of DL50 is very high - in rats
2.0 g/kg of body weight for oral administration and
0.875 g/kg for intraperitoneal administration [200].
Pepstatin distribution in mouse organs has been pre-
sented in Table 19. Low toxicity of pepstatin allows it
to be used to investigate processes dependent on
cathepsin D effect on culture cells [202]. Anti-cathep-
sin D antibodies have been also used to inhibit prote-
olysis in vivo. Antibodies are obtained by cells via
pinocytosis and accumulated in lysosomes. This caus-
es inhibition of degradation of the hemoglobin added
to a macrophage culture. Antibodies have no effect on
cell viability or pinocytosis. 
One inhibitor cannot inactivate all proteases of the
lysosomal extract. Only a mixture of inhibitors, each
inactivating protease of different catalytic site struc-
ture, may inhibit cell proteolysis [203]. A similar effect
can be achieved thanks to polyvalent immune serum
obtained after administration of the lysosomal extract
to experimental animals. The immune serum added to
a fibroblast culture was stored in lysosomes, which
showed lower activity of cathepsins, especially cathep-
sin D and reduced exogenous protein degradation
potential. Pinocytosis was impaired and lysosomes
enlarged. 
Determination of concentration, activity 
and tissue and cell location of cathepsin D
inhibitors 
The activity of cathepsin D is determined using a test,
in which: 1 - enzyme releases the reaction product in
an amount corresponding to the absorbance of 0.5; 2 -
inhibitor inhibits 50% of enzyme activity. The
inhibitor activity is calculated according to the formu-
la: inhibitor, U/ml/min = (d x r) : t, in which: d means
difference in the amount of the reaction products in a
test without and with inhibitor, r - inhibitor dilution, t
- time of incubation. Determination of the effect of the
preincubation time of protease with inhibitor on the
measurement outcome allows detection of its immedi-
ate or progressive action. A synthetic cathepsin D sub-
strate, namely Pro-Thr-Glu-Phe-Phe(NO2)-Arg-Leu
should be used for determinations [104]. The use of
protein substrate (hemoglobin) is not recommended
due to the fact that indirect degradation products
undergo further digestion and final degradation prod-
ucts may inhibit protease activity. Measurement of the
kinetic constants in the presence of many substrates
whose concentrations are varied may be biased.
The inhibitory constant dimension (Ki), i.e.
enzyme-inhibitor dissociation constant, is the measure
of inhibitor activity; the lower the Ki value, the higher
the affinity of inhibitor activity for the enzyme [204].
To compare the suppressive actions of various
inhibitors, their concentrations that reduce cathepsin D
activity by 50% (ID50), expressed in μm/1 l, are deter-
mined [204]. The enzyme-inhibitor molar ratio is
determined from a plot of cathepsin D activity correla-
tion (in %) as a function of enzyme-inhibitor molar
ratio [205,206] (Fig. 18). The curve bends at higher
inhibitor concentrations due to partial dissociation of
the complex. The inhibitor concentration that causes a
50% enzyme activity reduction is used for analysis.
Prior to the therapeutic application of the inhibitor, its
toxicity expressed by DL50 value should be deter-
mined. The activity of α2-M is measured through the
assessment of proteolytic activity reduction in a stan-
dard testing system. The α2-M concentration is
assayed, using antibodies, by the nephelometric
method, laser nephelometry and radial immunodiffu-
sion [208]. Cell and tissue α2-M localization is also
performed  [209].
Determination of activity and concentration of
cathepsin D inhibitors in bacterial and plant extracts
may appear biased as also proteases with acidic pH
optima can be present in the material [210]. These pro-
teases, either sensitive or insensitive to the inhibitors,
reduce the value of inhibitor activity - inhibit the activ-
ity (sensitive) and cause proteolytic inactivation
(insensitive). The outcome depends upon the pH of the
extraction fluid and temperature and time of extract
storage. In the case of stable micromolecular
inhibitors, proteases are inactivated thermally and by
means of trichloroacetic or perchloric acid.
Trichloroacetic acid is removed from the supernatant,
whereas perchloric acid is precipitated by means of
potassium hydrogen and inhibitor activity is deter-
mined as above. The outcome can also be affected by
the order in which reagents are added: inhibitor -
enzyme - substrate or inhibitor - substrate - enzyme
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Fig. 18. Titration of the cathepsin D active site [207].
[211]. The activity and concentration of inhibitors in
the plasma and systemic fluids are calculated per unit
of volume, in cell culture per cell count and in solid tis-
sues per 1g or 1 μg DNA.
Results of immunohistochemical assessment of
inhibitor distribution (mainly α2-M) in cells and tis-
sues have been presented in color microphotographs.
Reaction intensity is evaluated semiquantitatively with
the scale: lack of reaction (-), weak positive reaction
(±), positive reaction (+), strong positive reaction (++)
[212, 213]. Cathepsin D is localized in tissues by
means of biotin- and biman-labeled pepstatin [214,
215].
Conclusions                                                        
The use of inhibitors has broadened the knowledge of
the structure of the catalytic site, the mechanism of
action and contribution of cathepsin D to protein
degradation in lysosomes. Attempts have been also
made to apply the inhibitors in the therapy of diseases
occurring with cathepsin D involvement. Especially
cathepsin D inhibitors, including statin, play a role,
due to their low toxicity. The application range is even
wider as statin is also the basic component of certain
inhibitors of HIV protease [216-222] and of many
renin inhibitors used for the treatment of hypertension
and atherosclerosis [108, 223-226].
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